2 results
Approved WMOCompleted
Primary: progression-free survival in the GSK1120212-group in comparison with the docetaxel group. Secondary: safety and tolerability, response rate, duration of response, overall survival, PK.
Approved WMOCompleted
To assess the efficacy of GV-971 compared with placebo on cognition and global function in participants with mild to moderate Alzheimer's disease (AD).